Pooled efficacy favored ravulizumab, improving QMG (MD –2.91) and MG-ADL (MD –2.64) after ~25 weeks, despite substantial between-study heterogeneity. Clinically meaningful MG-ADL response (≥2-point ...
Weekly subcutaneous gefurulimab delivered early is linked to lasting symptom improvement in patients with generalized ...
100% of patients achieved rapid, sustained improvements across MG-ADL and QMG at 24 weeks, further increasing confidence in Phase 3 trial Totality of efficacy and safety data reinforces miv-cel’s ...
MedPage Today on MSN
Cemdisiran siRNA therapy demonstrates efficacy in myasthenia gravis
Investigational treatment improves outcomes without complete complement blockade ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results